摘要
背景:成胶质细胞瘤是主要脑瘤最常见的最恶性的种类,被认为在人类肿瘤最高死亡率之一。持续时间长且具有侵略性的外科切除手术是首选方法,即使通常是由高增值率和广泛入侵的特征而诊断的不明确的肿瘤。早期的诊断结合仔细的检测在成胶质细胞瘤治疗中很关键。核磁共振图像用于监测,但是该方法检测非常小的肿瘤时灵敏度还不够高。一个有效的方法是活组织检查,但是具有明显的发病率:侵略性更小的诊断和治疗检测不断地被研究。 方法:本文在Pubmed上主要针对近10年的论文进行了综述。 结论:近年来在成胶质细胞瘤细胞分泌细胞外囊泡(微囊和外来体)方面已经有所研究,反映了亲代细胞的分子特征以及能够躲避肿瘤微环境到达脑脊液和系统性血液循环。这些信息使我们考虑到在生物流体中将细胞外囊泡作为成胶质细胞瘤病理状态的标记物使用,并且将他们作为一种更灵活的液体切片仅仅通过一个血样检查或者采集脑脊液来获得更多诊断性的信息,跟进疾病进展,对临床治疗进行反馈。考虑到最有意思与分子相关作为成胶质细胞瘤标记物的细胞外囊泡和一些方法一样,目的为了将细胞外囊泡作为无细胞疫苗或治疗性分子运输工具使用。
关键词: 细胞放射,外来体,细胞外囊泡,成胶质细胞瘤,成胶质细胞瘤标记物,微泡,U251人脑胶质瘤细胞
图形摘要
Current Cancer Drug Targets
Title:Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Volume: 17 Issue: 3
关键词: 细胞放射,外来体,细胞外囊泡,成胶质细胞瘤,成胶质细胞瘤标记物,微泡,U251人脑胶质瘤细胞
摘要: Background: Glioblastoma is the most common and malignant form of primary brain cancer; it is characterized by one of the highest mortality among human cancers. Maximal and aggressive surgical resection is the first approach treatment even if not usually definitive, being the tumor characterized by a high proliferative rate and extensive invasion. Early diagnosis, associated to careful monitoring, is pivotal in glioblastoma treatment; Magnetic Resonance Imaging is used for monitoring purpose, but it’s not sensitive enough to detect very small tumors; a valid alternative could be a repeated biopsy, but it is associated to a significant morbidity: less invasive options for diagnosis and therapeutic monitoring are unfailingly researched.
Methods: A careful search was performed on PubMed, mainly considering papers in the last 10 years. Conclusion: In recent years it has begun to take hold the knowledge that glioblastoma cells secrete extracellular vesicles (microvesicles and exosomes), which mirror the molecular features of parental cells and are able to escape from tumor microenvironment, reaching cerebrospinal fluid and systemic blood circulation. Such information led to consider the possibility to use extracellular vesicles in biological fluids as markers of glioblastoma pathology and to use them as a more feasible “liquid-biopsy” to gain diagnostic information, follow the disease progression and the response to clinical treatment, just through a blood test or cerebrospinal fluid collection. The most interesting extracellular vesiclesassociated molecules studied as glioblastoma markers are taken into account, as well as approaches aiming to use extracellular vesicles as cell-free vaccines or vehicle of therapeutic molecules.Export Options
About this article
Cite this article as:
Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666160813182959
DOI https://dx.doi.org/10.2174/1568009616666160813182959 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Friend or Foe: UCHL3 Mediated Carcinogenesis and Current Approaches in Small Molecule Inhibitors’ Development
Current Medicinal Chemistry 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Clinical Cancer Drugs Ligand Conjugated Targeted Nanotherapeutics for Treatment of Neurological Disorders
Current Pharmaceutical Design Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Active Targeting Strategies for Anticancer Drug Nanocarriers
Current Drug Delivery Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets